cd19 - Robuta Search

https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1454913/full Frontiers | CD19: a promising target for systemic sclerosis Systemic sclerosis (SSc) is an autoimmune disease characterized by immune dysregulation, vascular damage, and fibrosis. B cells play a significant role in SS... frontiers cd19 promising target systemic https://pmc.ncbi.nlm.nih.gov/articles/PMC8363505/ CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B... Despite impressive progress, more than 50% of patients treated with CD19-targeting chimeric antigen receptor T cells (CAR19) experience progressive disease.... https://www.biospace.com/kite-pharma-to-present-clinical-biomarkers-from-patients-treated-with-anti-cd19-chimeric-antigen-receptor-t-cell-therapy-at-the-2015-asco-annual-meeti Kite Pharma To Present Clinical Biomarkers From Patients Treated With Anti-CD19 Chimeric Antigen... https://www.jci.org/articles/view/39748/pdf JCI - CD81 gene defect in humans disrupts CD19 complex formation and leads to antibody deficiency https://www.rcsb.org/structure/6AL4 RCSB PDB - 6AL4: CRYSTAL STRUCTURE OF ANTI-CD19 ANTIBODY B43 FAB CRYSTAL STRUCTURE OF ANTI-CD19 ANTIBODY B43 FAB rcsb pdb crystal structure https://www.jci.org/articles/view/125423/figure/4 JCI - CD19 CAR T cell product and disease attributes predict leukemia remission durability car t cell https://www.cancer.gov/publications/dictionaries/cancer-drug/def/751864 Definition of anti-CD19-CAR FMC63-28Z retroviral vector-transduced allogeneic T lymphocytes - NCI... Find technical definitions and synonyms by letter for drugs/agents used to treat patients with cancer or conditions related to cancer. Each entry includes... https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2020.573822/full Frontiers | Acute Graft-Versus-Host Disease After Humanized Anti-CD19-CAR T Therapy in Relapsed... We studied the acute graft-versus-host disease (GVHD) post humanized anti-CD19-CAR T therapy for relapsed B-ALL patients after allogeneic hematopoietic stem ... graft versus host disease https://www.jci.org/articles/view/87366/figure/4 JCI - Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed... https://www.cancer.gov/publications/dictionaries/cancer-drug/def/autologous-anti-cd19-abtcr-expressing-t-lymphocytes-eb103 Definition of autologous anti-CD19 AbTCR-expressing T lymphocytes EB103 - NCI Drug Dictionary - NCI Find technical definitions and synonyms by letter for drugs/agents used to treat patients with cancer or conditions related to cancer. Each entry includes... https://www.jci.org/articles/view/87366/sd/3 JCI - Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed... https://www.jci.org/articles/view/125423/figure/5 JCI - CD19 CAR T cell product and disease attributes predict leukemia remission durability car t cell https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-of-cd19-and-cd22-car-t-cells-to-treat-blood-cancers-in-children-and-young-people-carpall A trial of CD19 and CD22 CAR T-cells to treat blood cancers in children and young people (CARPALL) This trial was for children and young people with a leukaemia or lymphoma that had either come back or was likely to come back after treatment. https://www.fishersci.com/shop/products/mus-cd19-elisa-96t/50154135 Biotang Inc Mouse Cluster of differentiation 19,CD19 ELISA Kit, 96T, Quantity: | Fisher Scientific Shop Biotang Inc Mouse Cluster of differentiation 19,CD19 ELISA Kit, 96T at Fishersci.com https://pmc.ncbi.nlm.nih.gov/articles/PMC10499936/ Inherited CD19 Deficiency Does Not Impair Plasma Cell Formation or Response to CXCL12 - PMC The human CD19 antigen is expressed throughout B cell ontogeny with the exception of neoplastic plasma cells and a subset of normal plasma cells. CD19 plays a... https://pmc.ncbi.nlm.nih.gov/articles/PMC8516648/ CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with... Chimeric antigen receptor (CAR) T cells targeting CD19 or CD22 have shown remarkable activity in B cell acute lymphoblastic leukemia (B-ALL). The major cause... https://pmc.ncbi.nlm.nih.gov/articles/PMC5096828/ Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies -... Potent CD19-directed immunotherapies, such as chimeric antigen receptor T cells (CART) and blinatumomab, have drastically changed the outcome of patients with... https://www.jci.org/articles/view/87366/usage JCI - Usage information: Dual CD19 and CD123 targeting prevents antigen-loss relapses after... https://www.jci.org/articles/view/125423/table/1 JCI - CD19 CAR T cell product and disease attributes predict leukemia remission durability car t cell https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anti-cd3-cd19-cd20-trispecific-antibody-1a46 Definition of anti-CD3/CD19/CD20 trispecific antibody 1A46 - NCI Drug Dictionary - NCI Find technical definitions and synonyms by letter for drugs/agents used to treat patients with cancer or conditions related to cancer. Each entry includes... definition of https://www.cancer.gov/publications/dictionaries/cancer-drug/def/allogeneic-hypoimmune-anti-cd19-car-t-cells-sc291 Definition of allogeneic hypoimmune anti-CD19 CAR T cells SC291 - NCI Drug Dictionary - NCI Find technical definitions and synonyms by letter for drugs/agents used to treat patients with cancer or conditions related to cancer. Each entry includes... car t cells https://www.cancer.gov/research/participate/clinical-trials/intervention/anti-cd19-cd20-cd22-car-t-cells?pn=1 Clinical Trials Using Anti-CD19/CD20/CD22 CAR T-Cells - NCI NCI supports clinical trials that test new and more effective ways to treat cancer. Find clinical trials studying anti-cd19/cd20/cd22 car t-cells. car t cells clinical trials using anti cd19 https://www.jci.org/articles/view/125423/figure/1 JCI - CD19 CAR T cell product and disease attributes predict leukemia remission durability car t cell https://www.jci.org/articles/view/87366/pdf JCI - Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed... https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.987965/full Frontiers | The risk factors and early predictive model of hematotoxicity after CD19 chimeric... Hematotoxicity is the most common long-term adverse event after chimeric antigen receptor T cell (CAR-T) therapy. Here, a total of 71 patients with relapsed ... https://www.cancer.gov/research/participate/clinical-trials/intervention/autologous-anti-cd19-cd20-cd22-car-t-cells Clinical Trials Using Autologous Anti-CD19/CD20/CD22 CAR T-cells - NCI NCI supports clinical trials that test new and more effective ways to treat cancer. Find clinical trials studying autologous anti-cd19/cd20/cd22 car t-cells. car t cells clinical trials https://pmc.ncbi.nlm.nih.gov/articles/PMC10957466/ Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B... There is a pressing need for allogeneic chimeric antigen receptor (CAR)-immune cell therapies that are safe, effective and affordable. We conducted a phase 1/2... https://www.jci.org/articles/view/125423/figure/6 JCI - CD19 CAR T cell product and disease attributes predict leukemia remission durability car t cell https://www.jci.org/articles/view/87366/figure/6 JCI - Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed... https://www.cms.gov/medicare/coverage/ide/approved-ide-studies-items/bb16328-nct02652468- A Pilot Study to Assess Engraftment Using CliniMACS TCR-?/? and CD19 Depleted Stem Cell Grafts From... https://www.cancer.gov/publications/dictionaries/cancer-drug/def/autologous-cd19-targeted-car-t-cells-gc007f Definition of autologous CD19-targeted CAR-T cells GC007F - NCI Drug Dictionary - NCI Find technical definitions and synonyms by letter for drugs/agents used to treat patients with cancer or conditions related to cancer. Each entry includes... car t cells definition of https://www.biospace.com/promab-presents-promising-results-in-humanized-cd19-car-t-cells-trial ProMab Presents Promising Results in Humanized CD19 CAR-T Cells Trial - BioSpace Jul 27, 2020 - ProMab Biotechnology, Inc., a leading developer of CAR-T/NK cell technology for global life sciences, announced today it has successfully completed an... car t cells promising results https://www.muni.cz/vyzkum/publikace/1811812 In vivo antigen-negative escape to CART-19 caused by CD19 promotor hypermethylation. | Masarykova... https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2024.1404351/full Frontiers | Late events after anti-CD19 CAR T-cell therapy for relapsed/refractory B-cell... The short-term complications from CART are well characterized, but the long-term complications still need to be further investigated. Therefore, herein, we w... car t cell therapy https://pmc.ncbi.nlm.nih.gov/articles/PMC8821938/ A novel and efficient tandem CD19- and CD22-directed CAR for B cell ALL - PMC CD19-directed chimeric antigen receptor (CAR) T cells have yielded impressive response rates in refractory/relapse B cell acute lymphoblastic leukemia (B-ALL);... https://elifesciences.org/articles/52337/figures Figures and data in A dynamic interaction between CD19 and the tetraspanin CD81 controls B cell... The tetraspanin CD81 uses its ectodomain to export CD19, and the interaction of the two proteins is dynamically regulated by B cell activation state. https://pmc.ncbi.nlm.nih.gov/articles/PMC23503/ Impaired CD19 expression and signaling, enhanced antibody response to type II T independent antigen... The tetraspanin CD81 is ubiquitously expressed and associated with CD19 on B lymphocytes and with CD4 and CD8 on T lymphocytes. Analysis of mice with disrupted... https://pmc.ncbi.nlm.nih.gov/articles/PMC4933590/ T cells expressing CD19/CD20 bi-specific chimeric antigen receptors prevent antigen escape by... The adoptive transfer of T cells expressing anti-CD19 chimeric antigen receptors (CARs) has shown remarkable curative potential against advanced B-cell... https://pmc.ncbi.nlm.nih.gov/articles/PMC7126394/ Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or... Despite the impressive complete remission (CR) induced by CD19 CAR-T cell therapy in B-ALL, the high rate of complete responses is sometimes limited by the... https://www.cancer.gov/publications/dictionaries/cancer-drug/def/autologous-pd1-knockout-cd19-specific-car-t-cells-brl-201 Definition of autologous PD1-knockout CD19-specific CAR T cells BRL-201 - NCI Drug Dictionary - NCI Find technical definitions and synonyms by letter for drugs/agents used to treat patients with cancer or conditions related to cancer. Each entry includes... https://www.prnewswire.com/news-releases/gracell-biotechnologies-to-present-clinical-data-on-bcmacd19-dual-targeting-fastcar-t-gc012f-in-rrmm-and-b-nhl-and-donor-derived-car-t-gc007g-in-b-all-at-eha2023-congress-301822827.html Gracell Biotechnologies to Present Clinical Data on BCMA/CD19 Dual-Targeting FasTCAR-T GC012F in... /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to... https://www.jci.org/articles/view/87366/sd/1 JCI - Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed... https://www.cancer.gov/publications/dictionaries/cancer-drug/def/autologous-anti-cd19-car-t-cells-glpg5101 Definition of autologous anti-CD19 CAR T cells GLPG5101 - NCI Drug Dictionary - NCI Find technical definitions and synonyms by letter for drugs/agents used to treat patients with cancer or conditions related to cancer. Each entry includes... car t cells definition of https://www.agilent.com/en/product/clinical-flow-cytometry/reagents-for-clinical-flow-cytometry/clinical-single-color-antibodies/cd19-787306 Anti-human CD19 antibodies | Agilent Anti-human CD19 antibodies for use in flow cytometry. These single-color reagents are of value to the study of B cell lineage leukemias and lymphomas. Learn... anti human cd19 antibodies agilent https://www.jci.org/articles/view/87366/sd/2 JCI - Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed... https://www.cancer.gov/publications/dictionaries/cancer-drug/def/autologous-anti-cd19-car-t-cells-tbi-1501 Definition of autologous anti-CD19 CAR-T cells TBI-1501 - NCI Drug Dictionary - NCI Find technical definitions and synonyms by letter for drugs/agents used to treat patients with cancer or conditions related to cancer. Each entry includes... car t cells https://www.biospace.com/immpact-bio-awarded-8-million-cirm-grant-for-phase-1b-2-development-of-impt-514-a-cd19-cd20-bispecific-car-t-cell-therapy-for-refractory-lupus-nephritis-and-systemic-lupus-erythematosus ImmPACT Bio Awarded $8 Million CIRM Grant for Phase 1b/2 Development of IMPT-514, a CD19/CD20... Feb 28, 2024 - ImmPACT Bio Awarded $8 Million CIRM Grant for Phase 1b/2 Development of IMPT-514, a CD19/CD20 Bispecific CAR T-Cell Therapy for Refractory Lupus Nephritis and... https://pubhtml5.com/dfsqf/aqux/2022-Anti-CD19_chimeric_antigen_receptor_T_cells_secreting_anti-PD-L1_single-chain_variable_fragment_attenuate_PD-L1_mediated_T_cell_inhibition/ 2022-Anti-CD19 chimeric antigen receptor T cells secreting anti-PD-L1 single-chain variable... Looking for 2022-Anti-CD19 chimeric antigen receptor T cells secreting anti-PD-L1 single-chain variable fragment attenuate PD-L1 mediated T cell inhibition?... https://www.jci.org/assets/347554/powerpoint JCI - CD19 CAR T cell product and disease attributes predict leukemia remission durability car t cell https://pmc.ncbi.nlm.nih.gov/articles/PMC5363196/ Inducible Caspase-9 Selectively Modulates the Toxicities of CD19-Specific Chimeric Antigen... Immunotherapy with T cells expressing the chimeric antigen receptor (CAR) specific for the CD19 antigen (CD19.CAR-Ts) is a very effective treatment in B cell... caspase 9 https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.965224/full Frontiers | Efficacy and safety of CD19-specific CAR-T cell-based therapy in secondary central... Encouraging response has been achieved in relapsed/refractory (R/R) B-cell lymphoma treated by chimeric antigen receptor T (CAR-T) cells. The efficacy and sa... https://www.biospace.com/casi-pharmaceuticals-announces-cnct19-cd19-car-t-receives-china-breakthrough-therapy-designation CASI Pharmaceuticals Announces CNCT19 (CD19 CAR-T) Receives China Breakthrough Therapy Designation... Dec 23, 2020 - CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and... casi pharmaceuticals https://www.frontiersin.org/journals/cellular-and-infection-microbiology/articles/10.3389/fcimb.2024.1488607/full Frontiers | Persistent CD19+ B cell lymphopenia in critically ill COVID-19 patients 50 days after... IntroductionLong COVID (LC) poses a persistent challenge in clinical practice due to limited understanding of its etiology. LC is hypothesized to stem from a...